‘Follow The Money’: Sweden’s Calliditas Plans US Listing

CEO Says NASDAQ Float Will Position Biotech Better Before Pivotal Readout

 
• By Sten Stovall
  
US dollars
Calliditas lead asset Nefecon is targeting IgA nephropathy (Berger's disease) • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip